IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v22y2021i5d10.1007_s10198-021-01285-1.html
   My bibliography  Save this article

Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses

Author

Listed:
  • Mark Oppe

    (Axentiva Solutions, S.L.)

  • Daniela Ortín-Sulbarán

    (Almirall)

  • Carlos Vila Silván

    (Almirall)

  • Anabel Estévez-Carrillo

    (Axentiva Solutions, S.L.)

  • Juan M. Ramos-Goñi

    (Axentiva Solutions, S.L.)

Abstract

Background Uncertainty in model-based cost-utility analyses is commonly assessed in a probabilistic sensitivity analysis. Model parameters are implemented as distributions and values are sampled from these distributions in a Monte Carlo simulation. Bootstrapping is an alternative method that requires fewer assumptions and incorporates correlations between model parameters. Methods A Markov model-based cost–utility analysis comparing oromucosal spray containing delta-9-tetrahidrocannabinol + cannabidiol (Sativex®, nabiximols) plus standard care versus standard spasticity care alone in the management of multiple sclerosis spasticity was performed over a 5-year time horizon from the Belgian healthcare payer perspective. The probabilistic sensitivity analysis was implemented using a bootstrap approach to ensure that the correlations present in the source clinical trial data were incorporated in the uncertainty estimates. Results Adding Sativex® spray to standard care was found to dominate standard spasticity care alone, with cost savings of €6,068 and a quality-adjusted life year gain of 0.145 per patient over the 5-year analysis. The probability of dominance increased from 29% in the first year to 94% in the fifth year, with the probability of QALY gains in excess of 99% for all years considered. Conclusions Adding Sativex® spray to spasticity care was found to dominate standard spasticity care alone in the Belgian healthcare setting. This study showed the use of bootstrapping techniques in a Markov model probabilistic sensitivity analysis instead of Monte Carlo simulations. Bootstrapping avoided the need to make distributional assumptions and allowed the incorporation of correlating structures present in the original clinical trial data in the uncertainty assessment.

Suggested Citation

  • Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
  • Handle: RePEc:spr:eujhec:v:22:y:2021:i:5:d:10.1007_s10198-021-01285-1
    DOI: 10.1007/s10198-021-01285-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-021-01285-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-021-01285-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Lanting Lu & Hilary Pearce & Chris Roome & James Shearer & Iain A. Lang & Ken Stein, 2012. "Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis," PharmacoEconomics, Springer, vol. 30(12), pages 1157-1171, December.
    2. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629, November.
    3. Olsen, Jan Abel, 2009. "Principles in Health Economics and Policy," OUP Catalogue, Oxford University Press, number 9780199237814, November.
    4. Drummond, Michael F. & Sculpher, Mark J. & Torrance, George W. & O'Brien, Bernie J. & Stoddart, Greg L., 2005. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 3, number 9780198529453, November.
    5. Silvia Messina & Claudio Solaro & Isabella Righini & Roberto Bergamaschi & Simona Bonavita & Roberto Bruno Bossio & Vincenzo Brescia Morra & Gianfranco Costantino & Paola Cavalla & Diego Centonze & Gi, 2017. "Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-10, August.
    6. Wolfgang Greiner & Tom Weijnen & Martin Nieuwenhuizen & Siem Oppe & Xavier Badia & Jan Busschbach & Martin Buxton & Paul Dolan & Paul Kind & Paul Krabbe & Arto Ohinmaa & David Parkin & Montserat Roset, 2003. "A single European currency for EQ-5D health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 222-231, September.
    7. Alastair M. Gray & Oliver Rivero-Arias & Philip M. Clarke, 2006. "Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping," Medical Decision Making, , vol. 26(1), pages 18-29, January.
    8. Lanting Lu & Hilary Pearce & Chris Roome & James Shearer & Iain Lang & Ken Stein, 2012. "Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis," PharmacoEconomics, Springer, vol. 30(12), pages 1157-1171, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Eleanor Heather & Katherine Payne & Mark Harrison & Deborah Symmons, 2014. "Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models," PharmacoEconomics, Springer, vol. 32(2), pages 109-134, February.
    2. Manuel Gomes & Robert Aldridge & Peter Wylie & James Bell & Owen Epstein, 2013. "Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients," Applied Health Economics and Health Policy, Springer, vol. 11(2), pages 107-117, April.
    3. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    4. Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
    5. Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
    6. Rosarin Sruamsiri & Piyameth Dilokthornsakul & Chayanin Pratoomsoot & Nathorn Chaiyakunapruk, 2014. "A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding," PharmacoEconomics, Springer, vol. 32(8), pages 801-813, August.
    7. Claire McKenna & Karl Claxton, 2011. "Addressing Adoption and Research Design Decisions Simultaneously," Medical Decision Making, , vol. 31(6), pages 853-865, November.
    8. C. Elizabeth McCarron & Eleanor M. Pullenayegum & Lehana Thabane & Ron Goeree & Jean-Eric Tarride, 2013. "The Impact of Using Informative Priors in a Bayesian Cost-Effectiveness Analysis," Medical Decision Making, , vol. 33(3), pages 437-450, April.
    9. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    10. Andrija S Grustam & Nasuh Buyukkaramikli & Ron Koymans & Hubertus J M Vrijhoef & Johan L Severens, 2019. "Value of information analysis in telehealth for chronic heart failure management," PLOS ONE, Public Library of Science, vol. 14(6), pages 1-23, June.
    11. Fernando Alarid-Escudero & Karen M. Kuntz, 2020. "Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio," PharmacoEconomics, Springer, vol. 38(3), pages 285-296, March.
    12. Petra Menn & Reiner Leidl & Rolf Holle, 2012. "A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease," PharmacoEconomics, Springer, vol. 30(9), pages 825-840, September.
    13. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
    14. Kobelt, G., 2013. "Health Economics: An Introduction to Economic Evaluation," Monographs, Office of Health Economics, number 000004.
    15. Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast, 2013. "The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 197-209, April.
    16. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
    17. Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    18. Edward Wilson, 2015. "A Practical Guide to Value of Information Analysis," PharmacoEconomics, Springer, vol. 33(2), pages 105-121, February.
    19. Yesim Tozan & Pitcha Ratanawong & Valérie R Louis & Pattamaporn Kittayapong & Annelies Wilder-Smith, 2014. "Use of Insecticide-Treated School Uniforms for Prevention of Dengue in Schoolchildren: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 9(9), pages 1-9, September.
    20. Brandon S Walker & Richard E Nelson & Brian R Jackson & David G Grenache & Edward R Ashwood & Robert L Schmidt, 2015. "A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-20, July.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:22:y:2021:i:5:d:10.1007_s10198-021-01285-1. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: . General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.